About Our Company

PathCision Medicine is pioneering the development of precision medicines to address oncology and other diseases with critical unmet needs. At the forefront of its innovation is a groundbreaking antibody-drug conjugate (ADC) designed to penetrate tissue barriers and achieve exponentially higher drug accumulation in highly invasive and metastatic tumors. This breakthrough is powered by PathCision's proprietary machine learning-enabled multi-omics platform, which leverages deep insights from tissue pathology to unveil novel therapeutic pathways, setting a new standard in targeted treatment strategies.